Cite
HARVARD Citation
Cuppens, K. et al. (2022). HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. Lung cancer. pp. 1-10. [Online].